Clinical trial
An Adaptive Design, Phase I/IIa, Open Label, Multicentre, Single Dose Escalation and Multiple Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous and Subcutaneous Doses of SerpinPC in Healthy Male Volunteers and Male Participants with Severe Haemophilia a or B with or Without Inhibitors
NCT04073498 is registered in ClinicalTrials.gov with ApcinteX Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Adaptive Design, Phase I/IIa, Open Label, Multicentre, Single Dose Escalation and Multiple Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous and Subcutaneous Doses of SerpinPC in Healthy Male Volunteers and Male Participants with Severe Haemophilia a or B with or Without Inhibitors
- Lead sponsor
- ApcinteX Ltd
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- August 14, 2019
- Completion date
- September 26, 2024
- Enrollment
- 39 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.